There are two ways to talk about ketamine right now. One is the marketing version, where it is a miracle that fixes everything and the only question is how fast you can book. The other is the clinical version, where it is a genuinely important tool with real evidence behind it, real risks, real limits, and a specific set of people it is right for and a larger set of people it is not.
If you are looking for ketamine assisted psychotherapy austin, what you most need is not enthusiasm. It is a clinician who will tell you the truth about whether this is the right tool for your situation, build the psychiatric evaluation around that question first, and say no when no is the honest answer.
I practice the second version. This page is written in it.
What ketamine-assisted psychotherapy actually is
Ketamine is not new. It has been used as an anesthetic for over fifty years, with a long-established safety record in monitored settings. What is newer is its use in psychiatry, where at lower doses it produces rapid antidepressant effects through a different mechanism than standard antidepressants: it acts on the brain’s glutamate system rather than primarily on serotonin.
Two things distinguish the psychiatric use worth understanding.
The first is speed. Standard antidepressants typically take weeks. Ketamine’s effects can appear within hours to a day, though they are temporally limited, often lasting several days from a single exposure, which is why treatment is structured as a series rather than a single event.
The second is the therapy part, which is what “ketamine-assisted psychotherapy,” or KAP, actually refers to. The hypothesis, supported by a growing body of research, is that ketamine opens a window of increased neuroplasticity and cognitive flexibility, a period in which the brain is more able to form new patterns, and that structured psychotherapy delivered around that window can take deeper effect than it otherwise would. The medicine softens the ground. The therapy does the planting. KAP is the deliberate pairing of the two, as opposed to ketamine given alone in a purely medical model
What the evidence does and does not support
I want to be precise here, because precision is exactly what the marketing version omits.
Where the evidence is strongest: Ketamine has a substantial evidence base for treatment-resistant depression, meaning depression that has not responded to standard antidepressants, where it produces rapid and often meaningful improvement. There is also a real and growing signal for ketamine in PTSD, including trauma that has resisted other treatment. For the assisted-psychotherapy model specifically, current evidence suggests the combination is promising, particularly for treatment-resistant depression and PTSD, with some studies indicating KAP may outperform ketamine or psychotherapy alone.
Where the evidence is still developing, and I will say so plainly: The research on KAP is not settled. Study designs vary widely, long-term durability is an open question, and the benefits frequently require maintenance dosing rather than resolving permanently after one course. At least one 2025 study found that adding psychotherapy provided no additional benefit beyond ketamine alone in a real-world sample, which is exactly the kind of finding an honest practice has to hold alongside the promising ones. The truthful summary is that this is a promising, actively researched approach, not a proven cure, and anyone who tells you otherwise is selling rather than treating.
Racemic ketamine versus esketamine: an important distinction
These terms get blurred in marketing, and the difference matters.
Esketamine (brand name Spravato) is FDA-approved. As of January 2025 it is approved both on its own and alongside an oral antidepressant for adults with treatment-resistant depression, after inadequate response to at least two antidepressants. It is a nasal spray, it is a Schedule III controlled substance, and it is available only through a regulated safety program that requires it to be administered in a certified medical setting with monitoring afterward, because of the risks of sedation, dissociation, and misuse. It is worth knowing that esketamine has not been shown to prevent suicide or reduce suicidal thinking, so it is not a substitute for crisis care.
Racemic ketamine is the original anesthetic, used off-label for psychiatric purposes through various routes. Off-label is not a pejorative, much of good psychiatry is evidence-based off-label prescribing, but it does mean the rigor of the evaluation and the monitoring around it falls to the clinician rather than to a packaged regulatory program. That is precisely where a careful psychiatric model matters most.
I evaluate which, if either, fits the individual. The point of the distinction is that “ketamine” is not one thing, and the right form, route, and structure depend on the diagnosis, the history, and the risks particular to you.
Why this belongs inside psychiatry, not beside it
Here is my central position, and it is the thing that separates this practice from a ketamine clinic.
Ketamine is not a first step. It is a considered step, taken after a real diagnostic evaluation, because the wrong candidates can be genuinely harmed by the right drug. Ketamine carries cardiovascular effects, dissociative effects that are destabilizing for some people, a real potential for misuse, and bladder and other risks with frequent or unsupervised use. It is not appropriate for everyone, and there are conditions and histories where it is the wrong choice entirely.
A responsible psychiatric approach means the evaluation comes first and the medicine second. What is actually driving the depression or the trauma response? Has first-line treatment truly been optimized, or just attempted? Are there biological contributors, thyroid, hormonal, inflammatory, that change the picture? Is this person someone for whom dissociative treatment is stabilizing or destabilizing? Those questions are the work. The administration is the easy part, and the part everyone else leads with.
This matters with particular weight for women navigating hormonal transitions, perinatal depression, or trauma, where the surrounding biology shapes both the problem and the response to treatment, and where a fast intervention applied without that context can miss what is actually going on.
A note on the perinatal period
Because so much of my work is with women, one honest, evidence-based note. There is a real and growing research literature on ketamine and esketamine around the perinatal period, including studies on reducing postpartum depression, and the pharmacologic data on racemic ketamine and breastfeeding is relatively reassuring, with very low transfer into milk in the available studies. This is an area of active investigation, not settled practice, and it is exactly the kind of decision that should be made individually, with full attention to both mother and infant, rather than from either fear or hype. If this is your situation, it is a conversation worth having carefully.
How I work
- Evaluation first, always. A comprehensive psychiatric and biological assessment establishes whether a ketamine-assisted approach is appropriate at all, and what has to be addressed alongside or instead of it.
- The right form for the person. Where a ketamine approach fits, I determine which form and structure suit the diagnosis, history, and risk profile, within a properly monitored setting.
- Therapy integrated, not bolted on. The assisted-psychotherapy model is built around the work of integration, not treated as an add-on to a drug appointment.
- Honest candidacy, including no. If a ketamine-assisted approach is not right for you, or not right yet, I will tell you that directly and point you toward what is. That is not a lost sale. It is the standard of care.
Who this is for
If you have treatment-resistant depression or trauma that hasn’t yielded to standard treatment, if you are drawn to ketamine-assisted or psychedelic-assisted approaches but want a psychiatrist who will evaluate the whole picture before reaching for the medicine, and who will be honest with you about evidence and candidacy: I built this work for you.
If you are not a fit, or if the honest answer is that something else should come first, I will tell you, and I would rather tell you now than waste your time.
If you are in crisis or having thoughts of harming yourself, please get immediate help. Call or text 988 or go to the nearest emergency department. Ketamine treatment is not crisis care, and the evidence does not support it as a way to prevent suicide.
I keep a deliberately small roster so each evaluation can be this thorough. That’s by design.
The practice
Dr. Lauren Williams is a board-certified psychiatrist in Austin, Texas, providing comprehensive psychiatric evaluation and, where appropriate, ketamine-assisted and integrative approaches to treatment-resistant depression and trauma in high-functioning adults. Care is structured around thorough psychiatric and biological evaluation; brief medication management is not the model.
If you are considering ketamine assisted psychotherapy austin and want it done within real psychiatric care, you may request a consultation. We’ll both find out if it’s a fit.
Patient Questions
What is ketamine-assisted psychotherapy?
Ketamine-assisted psychotherapy (KAP) pairs medically supervised ketamine with structured psychotherapy. The rationale is that ketamine acts rapidly on the brain’s glutamate system and opens a window of increased neuroplasticity and cognitive flexibility, during which psychotherapy may take deeper effect. It is distinct from ketamine given alone in a purely medical model. Evidence is promising, especially for treatment-resistant depression and PTSD, but still developing.
Is ketamine therapy FDA-approved?
Partly. Esketamine (Spravato), a nasal spray derived from ketamine, is FDA-approved for treatment-resistant depression, as of January 2025 both on its own and with an oral antidepressant, and is given only in certified medical settings under a regulated safety program. Racemic ketamine is FDA-approved as an anesthetic and is used off-label for psychiatric purposes, which places greater responsibility on the supervising clinician for evaluation and monitoring.
What does ketamine treat?
The strongest psychiatric evidence is for treatment-resistant depression, where ketamine can produce rapid improvement. There is also a real and growing evidence base for PTSD and treatment-resistant trauma. It is being studied in other conditions, but evidence there is more preliminary. It is not appropriate for everyone and requires careful candidacy assessment.
What are the risks of ketamine treatment?
Ketamine can cause dissociation, sedation, nausea, and transient increases in blood pressure, and it carries a real potential for misuse, which is why esketamine is a controlled substance given only under monitoring. Frequent or unsupervised use carries additional risks, including to the bladder. It can be destabilizing for some people and is contraindicated in certain conditions, which is why a psychiatric evaluation should precede treatment.
Is ketamine safe while breastfeeding?
The available pharmacologic data on racemic ketamine suggests very low transfer into breast milk, which is relatively reassuring, but data is limited and the decision should be made individually with attention to both mother and infant. Repeated-dose intranasal esketamine has less safety data in breastfeeding and warrants more caution. This is a careful, case-by-case conversation, not a blanket yes or no
Who offers ketamine-assisted psychotherapy in Austin?
Dr. Lauren Williams provides comprehensive psychiatric evaluation and, where clinically appropriate, ketamine-assisted and integrative approaches for treatment-resistant depression and trauma in Austin, Texas, within a private-pay model that places diagnostic evaluation before treatment.
